Published in J Infect Dis on November 01, 2011
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med (2015) 2.08
Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infect Dis (2015) 1.88
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Ebolavirus in West Africa, and the use of experimental therapies or vaccines. BMC Biol (2014) 1.19
Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05
Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis (2011) 1.03
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop. Viruses (2014) 0.99
Vaccines for viral hemorrhagic fevers--progress and shortcomings. Curr Opin Virol (2013) 0.99
Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem Biol (2014) 0.97
Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS (2013) 0.96
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94
Digital sensing and sizing of vesicular stomatitis virus pseudotypes in complex media: a model for Ebola and Marburg detection. ACS Nano (2014) 0.93
Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis (2011) 0.91
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One (2014) 0.88
Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy. J Venom Anim Toxins Incl Trop Dis (2015) 0.87
Vesicular stomatitis virus with the rabies virus glycoprotein directs retrograde transsynaptic transport among neurons in vivo. Front Neural Circuits (2013) 0.85
Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine. Mol Pharm (2013) 0.84
Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. Vaccine (2012) 0.84
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol (2014) 0.83
Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res (2015) 0.82
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. J Infect Dis (2015) 0.82
Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 0.82
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol (2014) 0.81
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. PLoS One (2012) 0.81
Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.80
A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates. J Infect Dis (2015) 0.79
Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis (2015) 0.79
Hunting Viral Receptors Using Haploid Cells. Annu Rev Virol (2015) 0.79
Lassa and Marburg viruses elicit distinct host transcriptional responses early after infection. BMC Genomics (2014) 0.79
A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? Philos Trans R Soc Lond B Biol Sci (2017) 0.79
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays. Sci Rep (2016) 0.78
In Vivo Replication and Pathogenesis of Vesicular Stomatitis Virus Recombinant M40 Containing Ebola Virus L-Domain Sequences. Infect Dis (Auckl) (2012) 0.77
Ebola: facing a new transboundary animal disease? Dev Biol (Basel) (2013) 0.77
Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector. Virology (2014) 0.77
Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin. J Virol (2013) 0.76
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine (2016) 0.76
An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. J Infect Dis (2016) 0.76
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
Antigenic diversification is correlated with increased thermostability in a mammalian virus. Virology (2016) 0.75
A dead-end host: is there a way out? A position piece on the ebola virus outbreak by the international union of immunology societies. Front Immunol (2014) 0.75
Using simulation to aid trial design: Ring-vaccination trials. PLoS Negl Trop Dis (2017) 0.75
Host Transcriptional Response to Ebola Virus Infection. Vaccines (Basel) (2017) 0.75
Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine. NPJ Vaccines (2016) 0.75
Ebola Vaccine: How Far are we? J Clin Diagn Res (2017) 0.75
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Infectious rabies viruses from cloned cDNA. EMBO J (1994) 8.35
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07
Isolation and partial characterisation of a new strain of Ebola virus. Lancet (1995) 5.18
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A (1996) 3.54
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol (1998) 3.07
Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol (1999) 3.04
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology (1998) 2.81
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol (1997) 2.07
Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 1.78
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol (2002) 1.49
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol (2004) 1.46
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol (2006) 1.42
Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis (2007) 1.37
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol (2001) 1.37
Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg (1966) 1.34
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology (2002) 1.33
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol (2010) 1.29
Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines (2008) 1.23
Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol (2010) 1.22
Measles vaccines. Front Biosci (2008) 1.19
Epizootiology of vesicular stomatitis. Am J Public Health Nations Health (1957) 1.09
Vesicular stomatitis virus in Panama. Human serologic patterns in a cattle raising area. Am J Epidemiol (1967) 1.01
Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol (2003) 0.97
Role of VSV G antigen in the development of experimental spongiform encephalopathy in mice. Acta Neuropathol (1986) 0.94
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 6.11
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis (2007) 3.47
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Pneumonia from human coronavirus in a macaque model. N Engl J Med (2013) 2.47
Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog (2009) 2.44
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol (2004) 2.34
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A (2013) 2.29
Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 2.24
Pause on avian flu transmission research. Science (2012) 2.24
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol (2004) 2.09
The ecology of Ebola virus. Trends Microbiol (2007) 2.08
Disease modeling for Ebola and Marburg viruses. Dis Model Mech (2009) 2.07
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med (2013) 1.98
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med (2006) 1.92
The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One (2013) 1.88
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77
Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis (2011) 1.75
Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis). Comp Med (2010) 1.71
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One (2008) 1.67
Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines (2014) 1.67
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology (2005) 1.63
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Assembly and budding of Ebolavirus. PLoS Pathog (2006) 1.62
Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis (2006) 1.62
Antibody-dependent enhancement of Ebola virus infection. J Virol (2003) 1.62
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol (2005) 1.61
Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol (2006) 1.61
Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol (2010) 1.59
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep (2013) 1.55
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. PLoS Negl Trop Dis (2011) 1.53
A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol (2011) 1.53
Reverse genetics for crimean-congo hemorrhagic fever virus. J Virol (2003) 1.52
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis (2012) 1.51
Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol Cell Proteomics (2003) 1.49
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47
Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol (2005) 1.47
Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. J Virol (2010) 1.47
Generation of biologically contained Ebola viruses. Proc Natl Acad Sci U S A (2008) 1.47
Phylogeny of New World arenaviruses based on the complete coding sequences of the small genomic segment identified an evolutionary lineage produced by intrasegmental recombination. Biochem Biophys Res Commun (2002) 1.45
Viral hemorrhagic fever--a vascular disease? Thromb Haemost (2003) 1.43
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Detection of Lassa virus, Mali. Emerg Infect Dis (2010) 1.41
Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J Virol (2011) 1.40
Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine (2006) 1.38
Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis (2007) 1.37
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification. J Virol Methods (2006) 1.35
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg Infect Dis (2006) 1.35
Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol (2004) 1.34
Functional analysis of the noncoding regions of the Uukuniemi virus (Bunyaviridae) RNA segments. J Virol (2004) 1.33
Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis (2011) 1.33
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Replication-deficient ebolavirus as a vaccine candidate. J Virol (2009) 1.32
Ebola virus matrix protein VP40 uses the COPII transport system for its intracellular transport. Cell Host Microbe (2008) 1.31
Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain. Emerg Infect Dis (2015) 1.31
Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J Immunol Methods (2011) 1.31
Current ebola vaccines. Expert Opin Biol Ther (2012) 1.30
Inclusion bodies are a site of ebolavirus replication. J Virol (2012) 1.29
Rescue of Hantaan virus minigenomes. Virology (2003) 1.29
Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J Bioterror Biodef (2011) 1.28
RNA polymerase I-driven minigenome system for Ebola viruses. J Virol (2005) 1.27
Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J Virol Methods (2007) 1.27
Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol (2011) 1.26
Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog (2010) 1.25
Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha. J Infect Dis (2004) 1.24
Sequence determination of the Crimean-Congo hemorrhagic fever virus L segment. Virology (2004) 1.24
Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol (2011) 1.23
A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis (2011) 1.23
Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology (2007) 1.22
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology (2008) 1.21
A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol (2010) 1.21
Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. Proc Natl Acad Sci U S A (2008) 1.21
A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med (2012) 1.20
Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool. Emerg Infect Dis (2016) 1.20
Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. J Infect Dis (2007) 1.20
Ebolavirus in West Africa, and the use of experimental therapies or vaccines. BMC Biol (2014) 1.19
Rapid molecular strategy for filovirus detection and characterization. J Clin Microbiol (2006) 1.18